CERS (Cerus Corp) יחס שווי שוק לשווי בספרים
Cerus Corporation (CERS) operates on counter-cyclical demand, as blood component purification remains critical regardless of market conditions. This chart of stock quotes at the value of 6.87 confirms the resilience of a model protected by strict patent law and its status as an industry benchmark. The company is currently focusing on the global implementation of its technologies and the completion of new product trials in Western clinics.
%20-%20%D7%99%D7%97%D7%A1%20%D7%A9%D7%95%D7%95%D7%99%20%D7%A9%D7%95%D7%A7%20%D7%9C%D7%A0%D7%9B%D7%A1%D7%99%D7%9D%20%D7%A0%D7%A7%D7%99%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mvt4kixj.9g-7avve2o&start=20220704&end=20261029&filename=GURU_Markets_-_CERS_-_Cerus-Corporation_-_Market-Cap-to-Net-Assets-Ratio "CERS יחס שווי שוק לערך בספרים Cerus (04.07.2022 - 29.10.2026) | 👁️GURU.Markets👁️")
CERS (Cerus Corp.): פילוחים אנליטיים ודוחות לפי אינדיקטורים
This ratio measures the market premium over the net asset value, reflecting investor confidence in the company's capital stability and collateral base. Analyzing the historical relationship between market capitalization and book value reveals how the proprietary monopoly of Cerus Corporation (CERS) in blood safety and its significant pricing power maintain the company's valuation well above book value marks.